Cetrorelix in the treatment of female infertility and endometriosis

Dominique Finas*, Daniela Hornung, Klaus Diedrich, Askan Schultze-Mosgau

*Korrespondierende/r Autor/-in für diese Arbeit
16 Zitate (Scopus)


The use of cetrorelix within ovarian-stimulation protocols demonstrates several advantages compared with gonadotropin-releasing hormone (GnRH) agonist-containing protocols, which include, for example, significantly less time for analogue treatment and a reduction in the amount of gonadotropins needed. Furthermore, fewer side effects can be expected. There is no difference regarding endometrium quality and hormone profiles, and the results of assisted reproduction cycles are comparable. Cetrorelix also seems to be useful in the treatment of endometriosis which, in most cases, is an estrogen-dependent disease. Furthermore, fewer side effects occur with this agent (e.g., postmenopausal symptoms) and no estradiol add-back is needed. In the future, new nonpeptic GnRH antagonists are expected to be available for oral administration. Although they are still under investigation, these agents have the potential to improve patients' comfort and compliance.

ZeitschriftExpert Opinion on Pharmacotherapy
Seiten (von - bis)2155-2168
PublikationsstatusVeröffentlicht - 10.2006


Untersuchen Sie die Forschungsthemen von „Cetrorelix in the treatment of female infertility and endometriosis“. Zusammen bilden sie einen einzigartigen Fingerprint.